Published in final edited form as:

Expert Rev Mol Med. ; 11: e12. doi:10.1017/S1462399409001033.

CCAAT/enhancer-binding protein β : its role in breast cancer and associations with receptor tyrosine kinases

Cynthia A. Zahnow

Abstract

The CCAAT/enhancer-binding proteins (C/EBPs) are a family of leucine-zipper transcription factors that regulate gene expression to control cellular proliferation, differentiation, inflammation and metabolism. Encoded by an intronless gene, C/EBP β is expressed as several distinct protein isoforms (LAP1, LAP2, LIP) whose expression is regulated by the differential use of several in-frame translation start sites. LAP1 and LAP2 are transcriptional activators and are associated with differentiation, whereas LIP is frequently elevated in proliferative tissue and acts as a dominant-negative inhibitor of transcription. However, emerging evidence suggests that LIP can serve as a transcriptional activator in some cellular contexts, and that LAP1 and LAP2 might also have unique actions. The LIP:LAP ratio is crucial for the maintenance of normal growth and development, and increases in this ratio lead to aggressive forms of breast cancer. This review discusses the regulation of C/EBP β activity by post-translational modification, the individual actions of LAP1, LAP2 and LIP, and the functions and downstream targets that are unique to each isoform. The role of the C/EBP β isoforms in breast cancer is discussed and emphasis is placed on their interactions with receptor tyrosine kinases.

The CCAAT/enhancer-binding proteins (C/EBPs) are a family of b-ZIP transcription factors that are exclusively eukaryotic and bind as dimers to sequence-specific, double-stranded DNA to regulate gene transcription. The C/EBP family has important roles in cellular proliferation and differentiation, survival and/or apoptosis, metabolism, inflammation and transformation, and oncogene-induced senescence and tumorigenesis (Refs 1,2,3,4,5,6). They share a highly conserved, C-terminal, leucine-zipper dimerisation domain, adjacent to a basic DNA-binding region, together referred to as b-ZIP (Fig. 1a,b). The N-terminal domain is less conserved, but contains three short motifs, referred to as activation domains (Refs 7,8,9,10), which interact with transcriptional coactivators (Ref. 11) and components of the basal transcription apparatus (Ref. 12) (Fig. 1a). Numerous regulatory regions that hold C/EBP β in an intrinsically repressed state and inhibit its transcriptional activity have also been identified. For example, seven conserved regions (CR1–CR7) have been described, and two of these motifs, CR5 and CR7 (Fig. 1a), are known to interact with the N-terminal activation domains to inhibit the transcriptional activity of C/EBP β (Ref. 7). In addition, two inhibitory regulatory domains (RD1 and RD2) have been identified; RD1 constitutively inhibits the transactivation potential of C/EBP β by inducing a closed conformation that prevents access to the activation domains, whereas RD2 inhibits C/EBP β binding by inducing a conformation that interferes with the ability of the basic region to interact with DNA (Ref. 8). Phosphorylation or deletion of these inhibitory domains leads to activation of C/EBP β and increased transcriptional activity (Refs 7,8).

The C/EBP family consists of six members: C/EBP α , C/EBP β , C/EBP δ , C/EBP ϵ , C/EBP γ , and C/EBP ζ that were renamed using Greek nomenclature to indicate the chronological order of their discovery (Ref. 1) (Table 1). The protein for the founding member C/EBP α , was purified from rat liver in the mid-1980s by double-stranded DNA-affinity chromatography and interactions with the CCAAT box DNA motif (Refs 13,14). The cDNA for C/EBP α was cloned soon thereafter (Ref. 15) and led to the identification of the second member of the family, C/EBP β , (Refs 16,17,18,19) and an emerging family of C/EBP proteins.

C/EBP α , C/EBP β , C/EBP δ and C/EBP γ are encoded by intronless genes, whereas the genes for C/EBP ϵ and C/EBP ζ contain introns. C/EBP δ , C/EBP γ and C/EBP ζ (CHOP, C/EBP homologous protein) are each translated as a single protein, but C/EBP α (p42, p30) and C/EBP β (LAP1, LAP2 and LIP) are translated as multiple proteins, either by leaky ribosome scanning and the alternative use of multiple translation initiation codons in the same mRNA (Fig. 2), or via regulated proteolysis to generate LIP (Refs 20,21,22,23,24,25). C/EBP ϵ is also expressed as multiple isoforms (p32, p30, p27, p14); however, the mechanism involves differential splicing and the alternative use of promoters (Ref. 26).

The C/EBPs must dimerise to bind DNA (Refs 27,28), and in the presence of DNA, the basic region assumes an α -helical configuration and the protein structure becomes stabilised (Ref. 29). Because the bZIP domain is conserved, all the C/EBPs are capable of forming intrafamilial homodimers or heterodimers with each other. With the exception of C/EBP ζ (CHOP), all C/EBP dimers bind to the same DNA consensus sequence, RTTGCGYAAAY, where R is an A or G, and Y is C or T (Ref. 30). Although C/EBP ζ can dimerise with other C/EBPs, it contains two proline residues in the basic region that disrupt its ability to bind to DNA at the C/EBP consensus site (Ref. 31). Consequently, C/EBP ζ normally acts to inhibit the binding of other C/EBP family members to DNA; however, C/EBP ζ -C/EBP heterodimers can activate genes during conditions of cellular stress via the consensus sequence PuPuPuTGCAAT(A/C)CCC, where Pu represents a purine (Ref. 32). Thus, C/EBP ζ can either inhibit or activate gene transcription depending upon the cellular conditions. C/EBP γ can also inhibit gene transcription, but in a manner quite different to that of CHOP. C/EBP γ lacks the N-terminal activation domain and can still dimerise and bind to DNA, but blocks gene transcription in a dominant-negative manner by forming inactive heterodimers with C/EBP family members (Ref. 33). Similarly, of the four C/EBP ϵ isoforms (p32, p30, p27, p14), the 30 kDa product has a lower transactivation potential than the 32 kDa form, and the 14 kDa isoform lacks the N-terminal activation domain and thus serves as a dominant negative (Refs 26,34). This pattern of decreased activity in the smaller C/EBP isoforms is seen with C/EBP α . The C/EBP α 30 kDa isoform has a lower activating potential than the larger 42 kDa protein (Ref. 21). The C/EBP β isoforms will be discussed at greater detail later in this review. The smaller LAP2 isoform (34 kDa) is normally a stronger transactivator than the full-length LAP1 (38 kDa), and LIP (20 kDa) lacks the N-terminal activation domains and often functions as a dominant negative. Several reviews on C/EBP structure and function have been published (Refs 4,5,35,36,37).

Taken together, this information demonstrates that the transactivation potential of each C/EBP isoform can be quite different, and that heterodimerisation among C/EBP family members can result in a myriad of regulatory effects on gene expression. Moreover, the participants in a C/EBP heterodimer or homodimer are subject to variability and are dependent upon the availability of each family member. Species-specific and tissue-specific differences in C/EBP expression, physiological or pathophysiological stressors, and extracellular mediators that acutely regulate C/EBP expression might all play a role in regulating dimer composition and formation.

This review will focus on the family member C/EBP β , the regulation of its activity by post-translational modification, and the individual actions of the C/EBP β isoforms (LAP1, LAP2, and LIP). This review will also consider the role of LAP1, LAP2 and LIP in breast cancer and their associations with receptor tyrosine kinase signalling. Unfortunately, numerous published reports included in this review, have not specifically identified the C/EBP β isoform(s) in their study as either LAP1, LAP2 or LIP, but simply refer to them as C/EBP β . In these cases, the authors are probably referring to the more abundant and active LAP2 isoform, but might also be examining both LAP1 and LAP2 without discrimination.

Post-translational modifications of C/EBP β protein

Phosphorylation

Post-translational modifications such as, phosphorylation, acetylation, methylation and sumoylation, play crucial roles in the regulation of C/EBP β binding, transcriptional activity, protein–protein interactions and subcellular localisation (Fig. 3a and Table 2). C/EBP β is normally maintained in a repressed state by negative regulatory domains, which sterically inhibit its transactivation domains (Refs 7,8). Phosphorylation within the inhibitory domains can abolish this repressive effect, and in many cases, leads to an increase in the transcriptional activity of C/EBP β . C/EBP β phosphorylation occurs on numerous residues and is regulated via numerous signalling pathways, which include: Ras–MAPK (Refs 38,39,40), growth factors and glycogen synthase kinase 3 β (GSK3 β) (Refs 41,42,43), Ca²⁺/calmodulin-dependent protein kinase (Ref. 44), ribosomal S6 kinase (Refs 45,46), protein kinases A and C (Refs 47,48,49,50,51), and the cyclin-dependent kinase pathway CDK1–CDK2–CCNA2 (cyclinA) (Refs 52,43). For a list of the phosphorylated residues, effectors and cell types see Table 2.

Acetylation

Acetylation can also regulate the transcriptional activity of C/EBP β (Fig. 3A) and C/EBP β -responsive promoters are often differentially sensitive to different C/EBP β acetylation profiles (Ref. 53). For example, growth hormone stimulates acetylation of C/EBP β at Lys39 (Fig. 3A), which increases the ability of C/EBP β to mediate transcription of *Fos* (Ref. 53), whereas deacetylation of Lys39 by histone deacetylase 1 (HDAC1) decreases the C/EBP β -mediated transcription of target genes involved in adipogenesis (Ref. 54). Moreover, during glucocorticoid-stimulated preadipocyte differentiation, C/EBP β is acetylated at Lys98, Lys101 and Lys102 by the acetyl transferases GCN5 and PCAF, and this leads to a decrease in the interaction of HDAC1 with C/EBP β (Ref. 55). By contrast, acetylation at Lys215 or Lys216 decreases the binding activity of C/EBP β on the DNA-binding protein inhibitor *ID1* promoter, but deacetylation by HDAC1 can restore its transcriptional activation (Ref. 56).

Methylation

The Lys39 residue in C/EBP β not only serves as a substrate for acetylation, but also as a target for methylation. The histone lysine N-methyltransferase, H3 lysine-9-specific 3 (G9a) has been found to interact directly with Lys39 (Fig. 3A) in the N-terminal activation domain of C/EBP β (Ref. 57). This interaction results in methylation of Lys39 and repression of C/EBP β transcriptional activity (Ref. 57). Phosphorylation of C/EBP β seems to disrupt the interactions with G9a and to antagonise methylation. Lys39 thus serves as a target for either methylation or acetylation, is conserved in mouse, rat and chicken C/EBP β , and appears to serve an important regulatory role in C/EBP β transcriptional activity.

Sumoylation

Sumoylation is a reversible, post-translational modification that involves the covalent attachment of a small ubiquitin-like modifier (SUMO) protein to its substrate. Sumoylation

regulates gene expression by altering the subcellular localisation, nucleocytoplasmic trafficking, stability, activity and interactions of target proteins in both the nucleus and cytoplasm of most cells. Sumoylation of transcription factors most often leads to repression of transcriptional activity, but enhanced activity has been reported. C/EBP β is a SUMO target and modification by sumoylation usually impairs its transcriptional activity. A conserved, five amino acid motif (I/V/L-KXEP), located within the first inhibitory domain (RD1) of C/EBP β , contains a lysine residue (Lys132 in mouse, Lys173 in human) (Fig. 3a) that is the covalent site of attachment for SUMO1 and SUMO2/3 (Refs 58,59). SUMO2/3 targets only the full-length C/EBP β -LAP1 isoform, and impairs the ability of LAP1 to activate the cyclin D1 gene (*CCND1*) promoter without altering the subcellular location of LAP1 (Ref. 59). In murine T cells, sumoylation of C/EBP β and redistribution of nuclear C/EBP β to a more pericentric heterochromatin location, interferes with the C/EBP β -mediated repression of Myc expression but has no effect on the C/EBP β -mediated activation of the *IL4* gene (Ref. 60).

Actions of C/EBP β

C/EBP β regulates the development of many tissues, and genetically engineered mouse studies have provided much insight into the diverse biological actions of C/EBP β . Unfortunately, few mouse models have been developed to study the actions of the individual C/EBP β isoforms. For example, C/EBP β -knockout mouse models lack all three C/EBP β isoforms, and although 50-70% of the homozygous C/EBP β mice are viable on a mixed-strain background, these mice exhibit defects in numerous developmental processes (Table 3). By contrast, mice lacking only the 34 kDa LAP2 isoform have fewer developmental defects than null mice that lack all three isoforms – LAP1, LAP2 and LIP (Table 3). This finding is surprising in light of the fact that the LAP2 isoform is considered to be the most transcriptionally active of the C/EBP β isoforms (Ref. 8) and suggests that LAP1 and LAP2 might have distinct actions, and that LAP2 is not essential for C/EBP β -mediated development in most tissues. The distinct actions of LAP1 and LAP2 are discussed below.

Distinct functions of LAP1 and LAP2—The LAP1 and LAP2 isoforms differ from each other only in 21 amino acids at the N-terminus (Fig. 1b). This truncation of LAP2 is the result of internal translation initiation from the LAP2 alternative translational start codon, which is downstream of the LAP1 start codon (Figs 1 and 2). Numerous studies report that LAP2 is a stronger transactivator than LAP1, but the molecular mechanisms for this are unclear. The functional relevance of these N-terminal amino acids is still emerging, but the data thus far suggest that the N-terminal region may differentially regulate the activity of LAP1 and LAP2, in part via regulation of C/EBP β protein tertiary structure and unique N-terminal protein–protein interactions.

The N-terminal region of LAP1 is important for recruitment of the nucleosome-remodeling complex SWI–SNF, which activates silenced genes via chromatin remodelling and increases access of transcription factors to their binding sites (Ref. 61). Specifically, it was shown that the N-terminal region of LAP1 interacts with the vertebrate SWI2 homologues, hBRM (human brahma) and BRG1 (brm/SWI2-related gene), which comprise the functional core and mediate the assembly of the SWI–SNF complex (Ref. 61). Although the LAP isoforms are known to cooperate with Myb to activate myeloid-specific genes such as *mim-1* (MER1-repeat-containing imprinted transcript 1) (Refs 62,63), the recruitment of the SWI–SNF complex is now suspected to be important for the LAP1–Myb interaction and the consequent regulation of a subset of myeloid genes (Ref. 61).

Disulfide bond formation is also an important determinant of tertiary protein structure and protein activity. Murine LAP1, LAP2 and LIP contain six, five and two cysteines,

respectively, which participate in disulfide-bridge formation (Ref. 64) (Fig. 3b). Specifically, the N-terminal, 21 amino acids of LAP1 contain a cysteine at position 11, which can form a disulfide bridge with Cys33. It was demonstrated in the murine macrophage-like cell line P388D1(IL1) that disruption of the Cys11–Cys33 disulfide bond by redox modification or reducing conditions alters the protein structure of LAP1, and enhances its DNA-binding activity. Thus, LAP1 is selectively activated through a redox switch to regulate the lipopolysaccharide-induced expression of the IL-6 gene, whereas LAP2 and LIP appear to be insensitive to similar changes in redox state (Ref. 64).

Pro-inflammatory stimuli such as LPS, IL-1 β , IL-6 and TNF- α also induce the potent antioxidant enzyme, manganese superoxide dismutase (MnSOD), and C/EBP β is important in the IL-1 β -dependent regulation of MnSOD (Ref. 65). Specifically, LAP1 has been shown to activate MnSOD, whereas LAP2 and LIP block the IL-1 β -dependent induction of MnSOD (Ref. 65). Moreover, LAP2 but not LAP1, is known to activate the *CCND1* (cyclin D1) promoter (Ref. 66). The mechanism responsible for the differential activation of *CCND1* by LAP2 involves sumoylation and inactivation of LAP1 via SUMO2/3 (Ref. 59).

Specific N-terminal protein–protein interactions between LAP1 or LAP2 and other non-b-ZIP proteins are also important in the regulation of LAP1 and LAP2 activity. The N-terminal region of LAP1 contains a consensus motif that can interact with the EVH1 (enabled/VASP homology 1) domain of the Homer protein family (Ref. 67), which is important in synaptogenesis, synapse function, receptor trafficking and axon pathfinding. Homer-3, which is expressed in thymus, interacts with its EVH1 domain to reduce the transactivation potential of LAP1 (Ref. 67). Another example of the N-terminal 21 amino acids and their regulation of C/EBP β –protein interactions is provided by the preferential binding of the transcription factor, Nopp140 with LAP2. The lack of a Nopp140 interaction with LAP1 results in a more active LAP2 and transcriptional activation of AGP1 (α 1-acid glycoprotein) (Ref. 68).

These data demonstrate that LAP1 and LAP2 have unique actions and that in specific cellular contexts the LAP1:LAP2 ratio may be important for regulation of gene expression. The lack of developmental defects in LAP2-null mice also suggests that LAP1 or LIP can functionally replace LAP2 during development.

LIP normally acts to repress transcription but can also serve as a transcriptional activator

A few mouse models have analysed the actions of LIP via tissue-specific targeting in transgenic mice. For example, targeted expression of LIP to the mouse mammary gland leads to hyperplasia and tumorigenesis (Ref. 69), whereas expression of LIP in stromal or osteoblast cells results in osteopaenia, reduced bone formation (Ref. 70), malocclusion and incisor overgrowth (Ref. 71). Although it was hypothesised that LIP acted as a dominant negative in these studies, transcriptional activation was not ruled out.

As a consequence of translation from a C-terminal AUG start codon, LIP lacks all of the activation domain modules (AD1, AD2, AD3) and much of the negative regulatory domain (RD1) normally found in the larger C/EBP β -LAP isoforms (Fig. 1). LIP can thereby function to inhibit the transcriptional activity of other C/EBPs by competing for C/EBP consensus binding sites or by forming inactive heterodimers with other C/EBPs as a dominant negative (Ref. 20). However, emerging evidence suggests that LIP can serve as a transcriptional activator in some cellular contexts, then the mechanism might include the interactions of LIP with other, non-C/EBP, transcription factors, such as glucocorticoid receptor, NF- κ B, progesterone receptor B and the runt-related transcription factor Runx2.

LIP activates several genes involved in the acute-phase response. The lipopolysaccharide-mediated acute-phase response in mouse liver leads to a dramatic elevation in LIP, an increase in the LIP:LAP ratio and a LIP-mediated increase in transcription of the acute-phase gene *ORM1*, also known as α 1-acid glycoprotein (*AGPI*) (Ref. 72). Analyses have demonstrated that LIP preferentially binds to the acute-phase response element of the *AGPI* promoter with an affinity that is higher than that for LAP (Ref. 72). Early studies of the *AGPI* promoter identified and mapped C/EBP consensus sites in the region of the glucocorticoid response element (Refs 73,74), and others showed that LAP and ligand-activated glucocorticoid receptor interact directly via protein interactions with the bZIP structure to synergistically transactivate *AGPI* (Ref. 75). It is therefore possible that LIP activation of *AGPI* gene expression occurs via protein interactions with the glucocorticoid receptor; however, this has yet to be confirmed.

C/EBP β is also known as nuclear factor for interleukin-6 expression (NF-IL6) (Table 1), and was originally identified as an IL-1-induced transactivator of the *IL6* gene (Refs 76,18). Studies have shown that the bZIP domain of LIP is important for the LPS-induced transcription of an IL-6 promoter linked to a luciferase reporter in B lymphoblasts (Ref. 77). Moreover, an intact NF- κ B binding site on the *IL6* promoter was found to be necessary for C/EBP activity (Ref. 77), which agrees with an earlier study showing that C/EBP β and NF- κ B can synergistically activate the *IL6* promoter (Ref. 78). Numerous studies have demonstrated an interaction between the leucine zipper region of C/EBP family members and the Rel-homology domain of NF- κ B (Ref. 79). Taken together, these data suggest that LIP may in part, activate the *IL6* promoter via an interaction between the Rel-homology domain of NF- κ B and the leucine-zipper region of LIP.

Another example of LIP as transactivator is the functional association of progesterone receptor-A (PR-A) and progesterone receptor-B (PR-B) with both LIP and LAP in endometrial stromal cells (Ref. 80). LIP and PR-B physically bind and cooperate to activate luciferase reporter constructs containing progesterone-response elements (PREs) (Ref. 80). Although LAP was unable to enhance PR-B-dependent transcription of PRE-responsive promoters, PR-A was found to enhance LAP transactivation of C/EBP-responsive promoters. Consequently, a predominance of LIP and PR-B will activate PRE-driven promoters, whereas increases in LAP and PR-A favour expression of C/EBP β -dependent genes (Ref. 80). Although interactions have been demonstrated between the progesterone receptor and RelA (NF- κ B-p65) (Ref. 81), it is unknown whether LIP or LAP cooperates with NF- κ B on the PR-A or PR-B gene promoters.

LIP has also been shown to transcriptionally activate genes involved in osteoblast differentiation via interaction with Runx2. LIP expression is upregulated during osteoblast differentiation (Ref. 82) and downregulated during adipocyte differentiation (Ref. 83). During osteoblast differentiation, the LIP isoform interacts with and coactivates Runx2 to induce osteoblast differentiation while inhibiting adipogenesis (Ref. 82). Because LIP lacks a transactivation domain, it requires an interaction with Runx2 to function as a transcriptional activator of genes involved in osteoblast differentiation, such as the osteocalcin gene [*BGLAP*, bone γ -carboxyglutamate (gla) protein]. Consequently, LIP is unable to promote osteoblast differentiation in the absence of Runx2, whereas the LAP proteins are capable of driving differentiation in a Runx2-independent manner (Ref. 82).

Long-standing evidence suggests that LIP functions as a dominant negative on many promoters. However, evidence is emerging to support a role for LIP as a transcriptional activator of gene expression.

C/EBP β in breast cancer

The gene encoding C/EBP β (*CEBPB*) is not mutated in breast tumours. Few mutations have been identified in *CEBPB*, and those that do occur are not believed to contribute to epithelial cancers (Ref. 84). Similarly, the Wellcome Trust Sanger Institute Cancer Genome Project (<http://www.sanger.ac.uk/genetics/CGP/cosmic/>) has identified *CEBPB* as a gene that does not contain somatic mutations in human cancers. *CEBPB* may, however, be amplified in a small subset of breast neoplasia. A gain at chromosomal 20q13.13, which contains *CEBPB*, has been found to be associated with lobular carcinoma in situ of the breast (Ref. 85).

The expression level of C/EBP β mRNA in cancer was queried using Oncomine Research, a cancer-profiling database (<http://www.oncomine.org/>) (Ref. 86). Data analysis performed with the Oncomine 3.0 array database demonstrated that expression of C/EBP β mRNA is not altered in breast cancer or in breast cancer cell lines compared with normal breast tissue. Other gene expression studies have also shown that C/EBP β mRNA is unchanged and not altered in breast cancer upon stimuli such as oncogenic ErbB receptor activation (Refs 87,88). However, differences in C/EBP β mRNA expression are observed among a few breast cancer subtypes. For example, Oncomine analysis showed that a significant, but modest increase in C/EBP β mRNA is observed in oestrogen-receptor-negative breast cancers versus those tumours that are positive for the oestrogen receptor (Table 4) (Refs 89,90,91,92,93). Additionally, an elevation in C/EBP β mRNA is associated with metastatic breast cancer (Ref. 90), a high tumour grade (Refs 88,94,93) and an overall poorer prognosis (Table 4) (Ref. 90).

It is interesting to note that C/EBP β mRNA levels are not elevated in most breast cancers compared with normal tissue, but are increased in a more-aggressive subset of tumours versus the less-aggressive tumours. These data are somewhat surprising given that *CEBPB* expression is primarily regulated via post-transcriptional mechanisms, and mRNA levels would not necessarily be expected to be regulated in breast tumours. Moreover, these data suggest that transcriptional control or regulation of mRNA stability may be a mechanism for *CEBPB* expression in more aggressive breast cancers. Finally, increases in C/EBP β mRNA can lead to increased translation, increases in C/EBP β isoform expression and significant elevations in the LIP:LAP ratio, all of which have been observed in oestrogen-receptor-negative, aneuploid, highly proliferative breast tumours that are associated with a poor prognosis (Refs 95,96). An increase in the LIP:LAP ratio has also been linked to a defective transforming growth factor β (TGF- β)-dependent cytostatic response in metastatic breast cancer cells (Ref. 97). In pleural effusion samples isolated from patients with metastatic breast cancer, this study found an elevation in the LIP:LAP ratio in proliferative tumour cells that had lost their TGF- β cytostatic response, whereas LAP expression was in molar excess in those samples with a normal cytostatic response to TGF- β (Ref. 97). The forced overexpression of LAP2 in cells expressing an elevated LIP:LAP ratio restored the TGF β cytostatic response, and led to a significant reduction in the proliferative activity of these metastatic cells. The mechanism of LAP2 overexpression involves an association with the forkhead box protein FOXO and SMAD (mothers against decapentaplegic homologue) proteins to facilitate the activation of the cyclin-dependent kinase CDN2B, as well as the repression of Myc. Because an increase in LIP expression antagonises LAP2 activity, a high LIP:LAP ratio favours the inactivation of p15INK4b, activation of Myc and proliferative behaviour in metastatic breast cancer cells (Ref. 97). Taken together, these data suggest that C/EBP β has an important role in aggressive, high-grade metastatic breast cancer and that C/EBP β expression in these more-aggressive tumours might be regulated in part via changes in C/EBP β mRNA and alterations in the translational regulation of C/EBP β protein isoform expression.

Studies in genetically engineered mice have also identified a role for C/EBP β in mammary gland development and breast cancer (Table 3). Transgenic mice that overexpress LIP in the mammary gland develop focal and diffuse alveolar hyperplasia as well as invasive and non-invasive carcinomas (Ref. 69). Moreover, mammary glands from mice lacking C/EBP β exhibit delayed ductal outgrowth, distended ducts, decreased branching, reduced secretory activity and decreased levels of the milk proteins β -casein and whey acidic protein (WAP) (Refs 98,99). Ductal epithelial cells from the C/EBP β -null mice also showed decreased proliferation and an increase in the percentage of progesterone-positive (PR) cells compared with wild-type mice (Ref. 100). Interestingly, no deleterious effects in mammary gland development were observed in C/EBP $\beta^{M20A/M20A}$ mice, which lack LAP2 expression (Ref. 101). This result suggests that LAP2 is not essential for C/EBP β -mediated mammary gland development and that LAP1 and LIP might be able to compensate for the loss of LAP2.

Moreover, in cell culture studies overexpressing LIP in mouse mammary epithelial cells (Ref. 69), or fibroblasts (Ref. 22), LIP overexpression leads to a lack of contact inhibition, resulting in proliferation and foci formation. Although we and others have shown that both LAP1 and LAP2 are expressed in non-malignant, human mammary cells such as MCF10A cells (Ref. 102), and in tumours from breast cancer patients (Refs 95,97), others have shown that LAP1 is predominantly expressed in normal mammary cells, whereas LAP2 is restricted to dividing cells in both normal and neoplastic mammary epithelial cells (Ref. 66). Moreover, it was shown that overexpression of LAP2 in MCF10A cells leads to epithelial–mesenchymal transition and transformation (Ref. 103). However, in light of the results in the TGF- β study, it appears that LAP2 expression can also induce senescence or growth arrest when expressed in breast cancer cells containing elevated levels of LIP (Ref. 97). Taken together, these data suggest that aberrant expression of the C/EBP β isoforms can lead to aggressive breast cancer; however, the precise role of each individual isoform remains to be resolved.

Finally, C/EBP β might indirectly contribute to breast cancer progression via regulation of aromatase expression in breast stromal tissue (Ref. 104) and multidrug resistance (Refs 105,106,107). The multidrug transporter P-glycoprotein, encoded by *MDR1*, is associated with clinical multidrug resistance and a poor prognosis in breast cancer (Ref. 108). This gene is regulated by C/EBP β in HepG2 hepatoma cells (Ref. 105) and in MCF7 breast cancer cells (Ref. 106) via an inverted CCAAT box (Y box) (Ref. 107).

A role for C/EBP β in cell survival, apoptosis and senescence

The role of C/EBP β in cancer might be partly mediated via its actions in the regulation of cell survival and apoptosis. For example, C/EBP β is important in the survival of hepatic stellate cells that have DNA damage as a result of CCl₄-induced free-radical formation (Ref. 46), and in macrophages, which require C/EBP β expression for survival in response to Myc–Raf transformation (Ref. 109). C/EBP β has also been shown to promote cell survival by reducing p53 expression and activity in response to DNA damage (Refs 110,111). Reduced levels of C/EBP β can thereby sensitise cells to apoptosis, as observed in C/EBP β -null mice, which display resistance to DMBA-induced skin tumorigenesis via increases in apoptosis (Ref. 39).

In addition to its role in apoptosis, numerous studies have demonstrated that C/EBP β has a role in oncogene-induced senescence. Senescence is a state of irreversible growth arrest and can act as a barrier to malignant transformation. It has been demonstrated that forced expression of LAP2 can lead to cell cycle arrest in hepatocarcinoma cells (Ref. 112), keratinocytes (Ref. 113) and fibroblasts (Ref. 114). C/EBP β also cooperates with RB/E2F to implement Ras^{v12}-induced cellular senescence via an irreversible cell cycle arrest at the G1–

S boundary (Ref. 115). Finally, oncogene-induced senescence has been shown to involve C/EBP β -dependent expression of a proinflammatory cytokine or chemokine secretory programme (Refs 116,117). In summary, C/EBP β promotes the survival of some transformed cells while inducing growth arrest in others. Clearly, the regulation of survival, apoptosis and senescence by C/EBP β is highly context specific and worthy of further investigation.

Receptor tyrosine kinases, C/EBPs and breast cancer

Receptor tyrosine kinase signalling contributes to the development of numerous cancers and the epidermal growth factor (EGF) receptor, fibroblast growth factor (FGF) receptor, insulin receptor (IR) and insulin-like growth factor-1 (IGF-I) receptor subfamilies in particular, have important roles in mammary tumorigenesis. The interactions between C/EBP β and the EGF, FGF, IR and IGF-I receptor families and their relationship to breast cancer is discussed below.

Epithelial growth factor receptor family

The EGF family of receptor tyrosine kinases (ErbB1/EGFR, ErbB2, ErbB3 and ErbB4) are membrane-bound receptors with intrinsic ligand-activated, tyrosine kinase activity. Numerous growth factors bind to these receptors to initiate receptor dimerisation and the initiation of a kinase signalling cascade (Refs 118,119,120). Both the ErbB receptors and ligands play important roles in mammary development and in breast cancer and each of the ErbB receptors, as well as numerous ligands, are often overexpressed in breast tumours (Refs 121,122,123). In general, EGFR–ErbB1 signalling leads to increased LIP and LAP expression. In cultured mammary epithelial cells and in transgenic mice, ErbB1 (EGFR) signalling leads to an increase in C/EBP β -LIP protein expression (Fig. 4a) by a mechanism that includes the increased binding and activation of the RNA-binding protein CUG-binding protein 1 (CUG-BP1) to C/EBP β mRNA (Ref. 102). In a rat model of secondary hyperparathyroidism, activation of EGFR via TGF- α leads to elevated LIP expression, an increase in the proliferative activity of parathyroid cells and a decrease in the expression of the vitamin D receptor (Ref. 124). In human bronchial epithelial cells, lysophosphatidic acid activates EGFR signalling, which increases C/EBP β -LAP expression and leads to expression of cytochrome c oxidase (COX2) and prostaglandin release (Ref. 125). Unfortunately, LIP expression was not examined in this study. Taken together, these studies demonstrate that ErbB1–EGFR signalling can regulate the differential translation of the LAP and LIP isoforms, resulting in elevated LIP expression and an increased LIP:LAP ratio. Elevated LIP then contributes to the mitogenic effects of ErbB signalling by promoting proliferation and a more aggressive disease state. It remains to be determined whether LIP and LAP feedback to regulate EGFR expression.

Fibroblast growth factor receptor family

The FGF receptor family contains four receptor tyrosine kinases (FGFR1, FGFR2, FGFR3 and FGFR4) and 22 ligands that bind to and activate the various receptor isoforms (Refs 126,127). FGFs are different from other growth factors in that they bind to heparin sulphates as well as an FGF receptor to form a ternary signalling complex (Ref. 128). Strong evidence exists for a role of the FGF family in murine mammary tumorigenesis, and evidence in human breast cancer is slowly emerging (Ref. 126). In mouse studies, aberrant FGF signalling leads to hyperplastic growth and neoplasia (Refs 129,130). Moreover, numerous FGFs and their receptors are overexpressed in malignant human breast tissue (Refs 131,126,132,133,134,135,136,137,138,139).

Mapping studies have demonstrated that two single-base-pair changes in intron 2 of *FGFR2* lead to increases in the binding of C/EBP β (LAP) and Oct1/Runx2, and result in increased *FGFR2* mRNA expression (Ref. 140) (Fig. 4b). Elevations in FGF2R expression are observed in oestrogen-receptor-positive breast cancer (Ref. 137) and an *FGFR2* locus was recently found to be associated with a small, but significant increase in the risk of developing breast cancer (Refs 138,139). LAP and LIP also regulate the FGF-binding protein (*FGFBP1*) promoter in response to EGFR and p38 MAP kinase signalling (Ref. 141) (Fig. 4b). Binding of LAP to the *FGFBP1* promoter results in increased promoter activity, whereas LIP inhibits promoter activity (Ref. 141). The binding actions of FGFBP1 lead to increases in the activity of FGF1 and FGF2, and cell lines expressing both FGFBP1 and FGF2 are more tumorigenic and angiogenic (Ref. 142). Consequently, C/EBP β appears to be important in the EGFR regulation of FGF activity as well as the regulation of FGFR2 expression in breast epithelial cells (Refs 141,140). However, it is not yet known whether FGF signalling alters the LIP:LAP ratio.

Insulin-receptor family

The insulin, or insulin-like growth factor, family consists of three members: the insulin receptor, the insulin-like growth factor type 1 receptor (IGF-IR) and the insulin-receptor-related receptor (IRR). Both the insulin receptor (Refs 143,144,145,146) and the IGF-IR (Refs 147,148,149,150) are activated and expressed at elevated levels in malignant breast tumours and in breast cancer cell lines. Similarly, elevated serum levels of insulin (Refs 151,152) and IGF-I (Ref. 153), which are ligands for the insulin receptor and IGF-I receptor, respectively, are associated with breast cancer recurrence and a poor prognosis. Although the insulin receptor mediates mostly metabolic effects and the IGF-IR mitogenic effects, both insulin and IGF-I are capable of inducing metabolic or mitogenic effects depending on tissue distribution, and concentration of receptors and ligands (Ref. 154). Additionally, there is substantial crosstalk between insulin and IGF-I with either ligand binding to either receptor.

C/EBP β regulation of insulin levels and insulin receptor expression

Regulation of insulin

Expression of the insulin gene is controlled primarily at the level of transcription and C/EBP β has been shown to be a glucose-induced inhibitor of insulin gene transcription in pancreatic β -cells (Refs 155,156). Exposure of pancreatic β -cell lines to high glucose concentrations leads to an upregulation of C/EBP β -LAP expression (Ref. 155) and a reduction in insulin expression (Fig. 4c). Likewise, in the pancreatic β -cell line RIN-5F, increased expression of LAP inhibits insulin expression, whereas expression of LIP has no effect (Ref. 157). However, in non- β -cells the reverse is observed, and C/EBP β -LAP expression stimulates insulin promoter activity and transcription via a C/EBP β consensus binding motif (Fig. 4c) (Ref. 155).

In animal studies, C/EBP β expression is upregulated in pancreatic islets during the development of diabetes mellitus in two rat models, the Zucker diabetic fatty (*fa/fa*) rat and rats subjected to 90% pancreatectomy (Ref. 156). The elevations in C/EBP β expression, observed in response to sustained hyperglycaemia or hyperlipidaemia, appear to have a role in the downregulation of insulin gene expression during the development of diabetes mellitus (Fig. 4c). In mice, deletion of C/EBP β is associated with increased insulin action and decreased fatty acid mobilisation in skeletal muscle, lower fasting blood glucose levels and an overall increase in whole-body insulin sensitivity (Ref. 158).

Regulation of insulin receptor

In addition to insulin, C/EBP β can regulate transcription of the insulin receptor (Fig. 4c) as part of a larger nuclear protein complex containing the transcription factors HMGI-Y and Sp1 in HepG2 cells (Ref. 159). Taken together, these data suggest that C/EBP β regulates insulin sensitivity via regulation of insulin levels or regulation of insulin receptor expression.

Insulin regulation of C/EBP β expression and activity

Increased insulin signalling has been shown to regulate C/EBP β expression in liver, adipocytes and muscle tissue. For example, treatment of fully differentiated 3T3-L1 adipocytes with insulin leads to transient increases in expression of LAP and LIP (Fig. 4c) (Refs 160,161). Moreover, in liver tissue, both C/EBP β LAP and LIP isoforms are rapidly increased in H4IIE rat hepatoma cells treated with 10 nM insulin (Ref. 162); however, in diabetic mouse liver, LAP expression is downregulated by elevation of insulin concentration (Fig. 4c) (Ref. 163). In vascular smooth muscle cells, an increase in insulin signalling can lead to the upregulation of nuclear C/EBP β -LAP expression primarily via PI3K signalling (Ref. 164). Insulin signalling can suppress C/EBP β -LAP activity (Fig. 4c) via a mechanism that includes the Akt-mediated phosphorylation of p300/CBP, followed by the disruption and removal of p300/CBP from the activation domain of C/EBP β and a loss in the transactivation potential of C/EBP β (Ref. 165). In summary, C/EBP β participates in a complex relationship with insulin signalling. Not only does C/EBP β -LAP regulate insulin levels and expression of the insulin receptor, but insulin can also regulate C/EBP β isoform expression and activity.

C/EBP β regulation of IGF-I

In contrast to insulin signalling, less is known regarding the relationship between C/EBP β expression and IGF-I signalling. For example, it is not known whether C/EBP β regulates IGF-I receptor expression; however, loss of C/EBP β (LAP1, LAP2 and LIP) expression has been shown to lead to a disrupted IGF-I axis in rodent studies (Ref. 166). In the mammary gland of C/EBP β -null mice, the levels of IRS-1 are decreased and the expression pattern of IGF-BP5 and IGF-II are altered compared with wild-type mice (Fig 4D) (Ref. 166). Similarly, it is not known whether IGF-I signalling alters the LIP:LAP ratio; however, studies have shown that LAP expression can regulate IGF-I ligand levels. For example, in transformed bone-marrow-derived macrophages isolated from the C/EBP β -knockout mouse, IGF-I expression is decreased in response to the loss of C/EBP β expression (Fig. 4d) (Ref. 109). Similarly, in hepatocytes, the addition of C/EBP β -LAP to the human hepatoma cell line Hep3B increases IGF-I expression (Ref. 167). Overexpression of LIP alone appears to have no effect on IGF-1 promoter activity, but does abolish the transactivation induced by LAP (Fig 4d) (Ref. 167). In HepG2 cells, the protein kinase C (PKC) pathway has been implicated in the control of IGF-I gene regulation via a C/EBP site in the IGF-I promoter (Ref. 168). The mechanism involves the PKC-mediated activation of C/EBP β at both the transcriptional and post-translational level followed by binding of C/EBP β to the IGF-I gene promoter to induce transcription (Ref. 168). The C/EBPs also have a role in the regulation of IGF-I expression in bone cells, and might act as transcriptional coupling factors to coordinate bone remodelling in response to osteotropic hormones (Refs 169,170). In summary, the C/EBP β isoforms, and in particular, LAP, play a positive role in regulating IGF-I ligand expression as well as various members of the IGF-I axis.

Clinical implications

C/EBP β is considered to be a potential candidate for therapeutic intervention in epithelial cancers because of its role in the regulation of cell proliferation and differentiation, its associations with cancer and its non-essential cellular functions (Refs 171,172). However, transcription factors such as C/EBP β are difficult to target because they belong to protein families with redundant, overlapping functions and numerous binding partners. Moreover, C/EBP β acts as a convergence point to regulate numerous gene expression profiles and because of these wide-ranging cellular effects, target specificity remains a major challenge to the development of C/EBP β therapies. Specificity issues have, however, been successfully addressed for numerous transcription factors or enzymes that have similar broad-reaching actions. In fact, many of these drugs are currently showing promise in clinical trials and are not eliciting the expected off-target effects. Examples of these agents are enzyme inhibitors to histone deacetylases (HDACs) (Ref. 173), histone acetyl transferases (HATs) (Refs 174,175), Erk signalling (Ref. 176) and PI3K–Akt–mTOR signalling (Ref. 177), as well as inhibitors of the transcription factors NF- κ B (Ref. 178), p53 (Ref. 179), Stat3 (reviewed by Ref. 180) and the Notch pathway (Ref. 181). Because C/EBP β activity is regulated via post-translational phosphorylation, acetylation, sumoylation and methylation, numerous kinases, deacetylases, acetyltransferases, demethylases and methyltransferases, as described above, might soon become valuable targets in the regulation of C/EBP β activity.

Another difficulty in targeting and regulating C/EBP β activity is the lack of specificity in the interaction of C/EBP β with DNA. The C/EBP β DNA-binding site is a dyad symmetrical repeat, but substantial variations in sequence are common in most promoters and are well tolerated by C/EBP β . To make matters worse, the CCAAT box motif is not specific to C/EBP β , because most of the other C/EBP family members also bind to the same consensus sequence. Although specific targeting of the C/EBP β binding site might prove to be one of the more difficult targeting strategies, agents have been designed to block transcription factor binding to DNA. As an example, a high-throughput fluorescent microscopy screen has been used to identify several small molecules that bind to the basic region of C/EBP β and inhibit its binding to DNA (Ref. 182). The off-target effects and specificity of these agents remain to be examined. Despite the difficulties, advances in the targeting of transcription factors are being made, and several small molecules have been identified that successfully target the dimerisation of transcription factors, such as Stat3 (Ref. 183) and Myc (Ref. 184), or protein–protein interactions, such as those between p53 and the E3 ubiquitin-protein ligase MDM2 (Refs 185,186), and HIF-1 α and the aryl hydrocarbon receptor nuclear translocator ARNT (Ref. 187).

Outstanding research questions

Since the identification of the C/EBPs nearly 20 years ago (Ref. 15), numerous studies have revealed that the C/EBPs have pivotal roles in the control of cell fate, tissue development and malignant transformation. However, much still remains unknown regarding the individual and overlapping functions of each C/EBP family member and their protein isoforms. For example, the precise roles of LAP1, LAP2 and LIP in metastatic breast cancer are not clear and this makes it difficult to determine which isoform would represent the most effective therapeutic target. Mounting evidence suggests that LAP1, LAP2 and LIP have separate and distinct functions on some gene promoters and this is fascinating in light of the fact that all three bind to the same DNA-recognition sequence. Differences might exist in the binding partners for each isoform and the affinity or specificity of their binding to specific promoters. These questions will need to be addressed using endogenous genes and chromatin immunoprecipitation techniques coupled with proteomic analyses.

Studies in mice that either overexpress a particular C/EBP family member or are deficient for that C/EBP isoform have been crucial to our understanding of the importance of C/EBP in physiological and developmental processes such as metabolism, inflammation, immunity, haematopoiesis, diabetes, reproduction and cancer. Clearly, however, conditional knockouts, regulated knock-ins, and knockouts of more than one C/EBP family member will be necessary to decipher the functional redundancy that exists between C/EBPs as well as to identify the full range of actions for each C/EBP isoform. Progress has been made in our understanding of the molecular actions of the C/EBP superfamily but additional research should continue to focus on the characterisation of interacting proteins and transcriptional targets.

Acknowledgments

Acknowledgements and Funding: The author is currently funded by NIH grant R01 CA113795, the Susan G. Komen for the Cure Program, the Flight Attendant Medical Research Institute, the Hansen Foundation and the Johns Hopkins Breast Cancer Program. The author is grateful to Peter Johnson and Jeffrey Rosen for critical review of this manuscript and to the anonymous peer referees for their constructive comments. I apologise to all those authors whose work was not included in this review due to space limitations or oversight.

References

1. Cao Z, Umek RM, McKnight SL. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. *Genes and Development*. 1991; 5:1538–1552. [PubMed: 1840554]
2. Diehl AM. Roles of CCAAT/enhancer-binding proteins in regulation of liver regenerative growth. *Journal of Biological Chemistry*. 1998; 273:30843–30846. [PubMed: 9812973]
3. Poli V. The role of C/EBP isoforms in the control of inflammatory and native immunity functions. *Journal of Biological Chemistry*. 1998; 273:29279–29282. [PubMed: 9792624]
4. Zahnow CA. CCAAT/enhancer binding proteins in normal mammary development and breast cancer. *Breast Cancer Research*. 2002; 4:113–121. [PubMed: 12052253]
5. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. *Biochemical Journal*. 2002; 365:561–575. [PubMed: 12006103]
6. Sebastian T, Johnson PF. Stop and go: anti-proliferative and mitogenic functions of the transcription factor C/EBPbeta. *Cell Cycle*. 2006; 5:953–957. [PubMed: 16687924]
7. Kowenz-Leutz E, et al. Novel mechanism of C/EBP beta (NF-M) transcriptional control: activation through derepression. *Genes and Development*. 1994; 8:2781–2791. [PubMed: 7958933]
8. Williams SC, et al. CRP2 (C/EBP beta) contains a bipartite regulatory domain that controls transcriptional activation, DNA binding and cell specificity. *EMBO Journal*. 1995; 14:3170–3183. [PubMed: 7621830]
9. Angerer ND, et al. A short conserved motif is required for repressor domain function in the myeloid-specific transcription factor CCAAT/enhancer-binding protein epsilon. *Journal of Biological Chemistry*. 1999; 274:4147–4154. [PubMed: 9933609]
10. Williamson EA, et al. Identification of transcriptional activation and repression domains in human CCAAT/enhancer-binding protein epsilon. *Journal of Biological Chemistry*. 1998; 273:14796–14804. [PubMed: 9614080]
11. Mink S, Haenig B, Klempnauer KH. Interaction and functional collaboration of p300 and C/EBPbeta. *Molecular and Cellular Biology*. 1997; 17:6609–6617. [PubMed: 9343424]
12. Nerlov C, Ziff EB. CCAAT/enhancer binding protein-alpha amino acid motifs with dual TBP and TFIIB binding ability co-operate to activate transcription in both yeast and mammalian cells. *EMBO Journal*. 1995; 14:4318–4328. [PubMed: 7556073]
13. Graves BJ, Johnson PF, McKnight SL. Homologous recognition of a promoter domain common to the MSV LTR and the HSV tk gene. *Cell*. 1986; 44:565–576. [PubMed: 3004739]
14. Johnson PF, et al. Identification of a rat liver nuclear protein that binds to the enhancer core element of three animal viruses. *Genes and Development*. 1987; 1:133–146. [PubMed: 2824279]

15. Landschulz WH, et al. Isolation of a recombinant copy of the gene encoding C/EBP. *Genes and Development*. 1988; 2:786–800. [PubMed: 2850264]
16. Descombes P, et al. LAP, a novel member of the C/EBP gene family, encodes a liver-enriched transcriptional activator protein. *Genes and Development*. 1990; 4:1541–1551. [PubMed: 2253878]
17. Chang CJ, et al. Molecular cloning of a transcription factor, AGP/EBP, that belongs to members of the C/EBP family. *Molecular and Cellular Biology*. 1990; 10:6642–6653. [PubMed: 1701020]
18. Akira S, et al. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. *EMBO Journal*. 1990; 9:1897–1906. [PubMed: 2112087]
19. Poli V, Mancini FP, Cortese R. IL-6DBP, a nuclear protein involved in interleukin-6 signal transduction, defines a new family of leucine zipper proteins related to C/EBP. *Cell*. 1990; 63:643–653. [PubMed: 2171780]
20. Descombes P, Schibler U. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. *Cell*. 1991; 67:569–579. [PubMed: 1934061]
21. Ossipow V, Descombes P, Schibler U. CCAAT/enhancer-binding protein mRNA is translated into multiple proteins with different transcription activation potentials. *Proceedings of the National Academy of Sciences of the United States of America*. 1993; 90:8219–8223. [PubMed: 8367486]
22. Calkhoven CF, Muller C, Leutz A. Translational control of C/EBPalpha and C/EBPbeta isoform expression. *Genes and Development*. 2000; 14:1920–1932. [PubMed: 10921906]
23. Xiong W, et al. Regulation of CCAAT/enhancer-binding protein-beta isoform synthesis by alternative translational initiation at multiple AUG start sites. *Nucleic Acids Research*. 2001; 29:3087–3098. [PubMed: 11452034]
24. Lin FT, et al. A 30-kDa alternative translation product of the CCAAT/enhancer binding protein alpha message: transcriptional activator lacking antimitotic activity. *Proceedings of the National Academy of Sciences of the United States of America*. 1993; 90:9606–9610. [PubMed: 8415748]
25. Welm AL, Timchenko NA, Darlington GJ. C/EBPalpha regulates generation of C/EBPbeta isoforms through activation of specific proteolytic cleavage. *Molecular and Cellular Biology*. 1999; 19:1695–1704. [PubMed: 10022857]
26. Yamanaka R, et al. CCAAT/enhancer binding protein epsilon is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing. *Proceedings of the National Academy of Sciences of the United States of America*. 1997; 94:6462–6467. [PubMed: 9177240]
27. Vinson CR, Sigler PB, McKnight SL. Scissors-grip model for DNA recognition by a family of leucine zipper proteins. *Science*. 1989; 246:911–916. [PubMed: 2683088]
28. Agre P, Johnson PF, McKnight SL. Cognate DNA binding specificity retained after leucine zipper exchange between GCN4 and C/EBP. *Science*. 1989; 246:922–926. [PubMed: 2530632]
29. Moll JR, et al. Magnesium is required for specific DNA binding of the CREB B-ZIP domain. *Nucleic Acids Research*. 2002; 30:1240–1246. [PubMed: 11861917]
30. Osada S, et al. DNA binding specificity of the CCAAT/enhancer-binding protein transcription factor family. *Journal of Biological Chemistry*. 1996; 271:3891–3896. [PubMed: 8632009]
31. Ron D, Habener JF. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. *Genes and Development*. 1992; 6:439–453. [PubMed: 1547942]
32. Ubeda M, et al. Stress-induced binding of the transcriptional factor CHOP to a novel DNA control element. *Molecular and Cellular Biology*. 1996; 16:1479–1489. [PubMed: 8657121]
33. Cooper C, et al. Ig/EBP (C/EBP gamma) is a transdominant negative inhibitor of C/EBP family transcriptional activators. *Nucleic Acids Research*. 1995; 23:4371–4377. [PubMed: 7501458]
34. Lekstrom-Himes JA. The role of C/EBP(epsilon) in the terminal stages of granulocyte differentiation. *Stem Cells*. 2001; 19:125–133. [PubMed: 11239167]
35. Grimm SL, Rosen JM. The role of C/EBPbeta in mammary gland development and breast cancer. *Journal of Mammary Gland Biology and Neoplasia*. 2003; 8:191–204. [PubMed: 14635794]
36. Vinson C, et al. Classification of human B-ZIP proteins based on dimerization properties. *Molecular and Cellular Biology*. 2002; 22:6321–6335. [PubMed: 12192032]

37. Takiguchi M. The C/EBP family of transcription factors in the liver and other organs. *International Journal of Experimental Pathology*. 1998; 79:369–391. [PubMed: 10319019]
38. Nakajima T, et al. Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. *Proceedings of the National Academy of Sciences of the United States of America*. 1993; 90:2207–2211. [PubMed: 8384717]
39. Zhu S, et al. CCAAT/enhancer binding protein-beta is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling. *Proceedings of the National Academy of Sciences of the United States of America*. 2002; 99:207–212. [PubMed: 11756662]
40. Mo X, et al. Ras induces mediator complex exchange on C/EBP beta. *Molecular Cell*. 2004; 13:241–250. [PubMed: 14759369]
41. Liao J, et al. CCAAT/enhancer-binding protein beta (C/EBPbeta) and C/EBPdelta contribute to growth hormone-regulated transcription of c-fos. *Journal of Biological Chemistry*. 1999; 274:31597–31604. [PubMed: 10531366]
42. Piwien-Pilipuk G, et al. Growth hormone regulates phosphorylation and function of CCAAT/enhancer-binding protein beta by modulating Akt and glycogen synthase kinase-3. *Journal of Biological Chemistry*. 2001; 276:19664–19671. [PubMed: 11278638]
43. Tang QQ, et al. Sequential phosphorylation of CCAAT enhancer-binding protein beta by MAPK and glycogen synthase kinase 3beta is required for adipogenesis. *Proceedings of the National Academy of Sciences of the United States of America*. 2005; 102:9766–9771. [PubMed: 15985551]
44. Wegner M, Cao Z, Rosenfeld MG. Calcium-regulated phosphorylation within the leucine zipper of C/EBP beta. *Science*. 1992; 256:370–373. [PubMed: 1314426]
45. Buck M, et al. Phosphorylation of rat serine 105 or mouse threonine 217 in C/EBP beta is required for hepatocyte proliferation induced by TGF alpha. *Molecular Cell*. 1999; 4:1087–1092. [PubMed: 10635333]
46. Buck M, et al. C/EBPbeta phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival. *Molecular Cell*. 2001; 8:807–816. [PubMed: 11684016]
47. Metz R, Ziff E. cAMP stimulates the C/EBP-related transcription factor rNFIL-6 to trans-locate to the nucleus and induce c-fos transcription. *Genes and Development*. 1991; 5:1754–1766. [PubMed: 1655570]
48. Trautwein C, et al. Transactivation by NF-IL6/LAP is enhanced by phosphorylation of its activation domain. *Nature*. 1993; 364:544–547. [PubMed: 8336793]
49. Trautwein C, et al. Protein kinase A and C site-specific phosphorylations of LAP (NF-IL6) modulate its binding affinity to DNA recognition elements. *Journal of Clinical Investigation*. 1994; 93:2554–2561. [PubMed: 8200992]
50. Mahoney CW, et al. Phosphorylation of CCAAT-enhancer binding protein by protein kinase C attenuates site-selective DNA binding. *Journal of Biological Chemistry*. 1992; 267:19396–19403. [PubMed: 1527059]
51. Chinery R, et al. Antioxidant-induced nuclear translocation of CCAAT/enhancer-binding protein beta. A critical role for protein kinase A-mediated phosphorylation of Ser299. *Journal of Biological Chemistry*. 1997; 272:30356–30361. [PubMed: 9374525]
52. Shuman JD, et al. Cell cycle-dependent phosphorylation of C/EBPbeta mediates oncogenic cooperativity between C/EBPbeta and H-RasV12. *Molecular and Cellular Biology*. 2004; 24:7380–7391. [PubMed: 15314150]
53. Cesena TI, et al. CCAAT/enhancer-binding protein (C/EBP) beta is acetylated at multiple lysines: acetylation of C/EBPbeta at lysine 39 modulates its ability to activate transcription. *Journal of Biological Chemistry*. 2007; 282:956–967. [PubMed: 17110376]
54. Cesena TI, et al. Acetylation and deacetylation regulate CCAAT/enhancer binding protein beta at K39 in mediating gene transcription. *Molecular and Cellular Endocrinology*. 2008; 289:94–101. [PubMed: 18486321]
55. Wiper-Bergeron N, et al. Glucocorticoid-stimulated preadipocyte differentiation is mediated through acetylation of C/EBPbeta by GCN5. *Proceedings of the National Academy of Sciences of the United States of America*. 2007; 104:2703–2708. [PubMed: 17301242]

56. Xu M, et al. STAT5-induced Id-1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPbeta. *EMBO Journal*. 2003; 22:893–904. [PubMed: 12574125]
57. Pless O, et al. G9a-mediated lysine methylation alters the function of CCAAT/enhancer-binding protein-beta. *Journal of Biological Chemistry*. 2008; 283:26357–26363. [PubMed: 18647749]
58. Melchior F. SUMO–nonclassical ubiquitin. *Annual Review of Cell and Developmental Biology*. 2000; 16:591–626.
59. Eaton EM, Sealy L. Modification of CCAAT/enhancer-binding protein-beta by the small ubiquitin-like modifier (SUMO) family members, SUMO-2 and SUMO-3. *Journal of Biological Chemistry*. 2003; 278:33416–33421. [PubMed: 12810706]
60. Berberich-Siebelt F, et al. SUMOylation interferes with CCAAT/enhancer-binding protein beta-mediated c-myc repression, but not IL-4 activation in T cells. *Journal of Immunology*. 2006; 176:4843–4851.
61. Kowenz-Leutz E, Leutz A. A C/EBP beta isoform recruits the SWI/SNF complex to activate myeloid genes. *Molecular Cell*. 1999; 4:735–743. [PubMed: 10619021]
62. Ness SA, et al. Myb and NF-M: combinatorial activators of myeloid genes in heterologous cell types. *Genes and Development*. 1993; 7:749–759. [PubMed: 7684005]
63. Burk O, et al. Synergistic activation of the chicken mim-1 gene by v-myb and C/EBP transcription factors. *EMBO Journal*. 1993; 12:2027–2038. [PubMed: 8491193]
64. Su WC, et al. Differential activation of a C/EBP beta isoform by a novel redox switch may confer the lipopolysaccharide-inducible expression of interleukin-6 gene. *Journal of Biological Chemistry*. 2003; 278:51150–51158. [PubMed: 14530280]
65. Qiu X, et al. Distinct functions of CCAAT enhancer-binding protein isoforms in the regulation of manganese superoxide dismutase during interleukin-1beta stimulation. *Journal of Biological Chemistry*. 2008; 283:25774–25785. [PubMed: 18559338]
66. Eaton EM, et al. Characterization of C/EBPbeta isoforms in normal versus neoplastic mammary epithelial cells. *Journal of Cellular Physiology*. 2001; 189:91–105. [PubMed: 11573208]
67. Ishiguro K, Xavier R. Homer-3 regulates activation of serum response element in T cells via its EVH1 domain. *Blood*. 2004; 103:2248–2256. [PubMed: 14645007]
68. Lee YM, et al. Transcriptional induction of the alpha-1 acid glycoprotein (AGP) gene by synergistic interaction of two alternative activator forms of AGP/enhancer-binding protein (C/EBP beta) and NF-kappaB or Nopp140. *Molecular and Cellular Biology*. 1996; 16:4257–4263. [PubMed: 8754826]
69. Zahnow CA, et al. A role for CCAAT/enhancer binding protein beta-liver-enriched inhibitory protein in mammary epithelial cell proliferation. *Cancer Research*. 2001; 61:261–269. [PubMed: 11196172]
70. Harrison JR, et al. Col1a1 promoter-targeted expression of p20 CCAAT enhancer-binding protein beta (C/EBPbeta), a truncated C/EBPbeta isoform, causes osteopenia in transgenic mice. *Journal of Biological Chemistry*. 2005; 280:8117–8124. [PubMed: 15598659]
71. Savage T, et al. Mandibular phenotype of p20C/EBPbeta transgenic mice: Reduced alveolar bone mass and site-specific dentin dysplasia. *Bone*. 2006; 39:552–564. [PubMed: 16682266]
72. An MR, et al. Evidence for posttranscriptional regulation of C/EBPalpha and C/EBPbeta isoform expression during the lipopolysaccharide-mediated acute-phase response. *Molecular and Cellular Biology*. 1996; 16:2295–2306. [PubMed: 8628296]
73. Williams P, et al. AGP/EBP(LAP) expressed in rat hepatoma cells interacts with multiple promoter sites and is necessary for maximal glucocorticoid induction of the rat alpha-1 acid glycoprotein gene. *Molecular and Cellular Biology*. 1991; 11:4959–4965. [PubMed: 1717823]
74. Ratajczak T, et al. Multiple elements within the glucocorticoid regulatory unit of the rat alpha 1-acid glycoprotein gene are recognition sites for C/EBP. *Journal of Biological Chemistry*. 1992; 267:11111–11119. [PubMed: 1597449]
75. Nishio Y, et al. A nuclear factor for interleukin-6 expression (NF-IL6) and the glucocorticoid receptor synergistically activate transcription of the rat alpha 1-acid glycoprotein gene via direct protein-protein interaction. *Molecular and Cellular Biology*. 1993; 13:1854–1862. [PubMed: 8441418]

76. Isshiki H, et al. Constitutive and interleukin-1 (IL-1)-inducible factors interact with the IL-1-responsive element in the IL-6 gene. *Molecular and Cellular Biology*. 1990; 10:2757–2764. [PubMed: 2111442]
77. Hu HM, et al. The C/EBP bZIP domain can mediate lipopolysaccharide induction of the proinflammatory cytokines interleukin-6 and monocyte chemoattractant protein-1. *Journal of Biological Chemistry*. 2000; 275:16373–16381. [PubMed: 10748205]
78. Matsusaka T, et al. Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. *Proceedings of the National Academy of Sciences of the United States of America*. 1993; 90:10193–10197. [PubMed: 8234276]
79. Stein B, Cogswell PC, Baldwin AS Jr. Functional and physical associations between NF-kappa B and C/EBP family members: a Rel domain-bZIP interaction. *Molecular and Cellular Biology*. 1993; 13:3964–3974. [PubMed: 8321203]
80. Christian M, et al. Functional association of PR and CCAAT/enhancer-binding protein beta isoforms: promoter-dependent cooperation between PR-B and liver-enriched inhibitory protein, or liver-enriched activatory protein and PR-A in human endometrial stromal cells. *Molecular Endocrinology*. 2002; 16:141–154. [PubMed: 11773445]
81. Kalkhoven E, et al. Negative interaction between the RelA(p65) subunit of NF-kappaB and the progesterone receptor. *Journal of Biological Chemistry*. 1996; 271:6217–6224. [PubMed: 8626413]
82. Hata K, et al. A CCAAT/enhancer binding protein beta isoform, liver-enriched inhibitory protein, regulates commitment of osteoblasts and adipocytes. *Molecular and Cellular Biology*. 2005; 25:1971–1979. [PubMed: 15713650]
83. Tang QQ, Otto TC, Lane MD. CCAAT/enhancer-binding protein beta is required for mitotic clonal expansion during adipogenesis. *Proceedings of the National Academy of Sciences of the United States of America*. 2003; 100:850–855. [PubMed: 12525691]
84. Vegesna V, et al. C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. *Leukemia Research*. 2002; 26:451–457. [PubMed: 11916518]
85. Mastracci TL, et al. Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferation in the breast. *Genes, Chromosomes and Cancer*. 2006; 45:1007–1017. [PubMed: 16897748]
86. Rhodes DR, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. *Neoplasia*. 2004; 6:1–6. [PubMed: 15068665]
87. Alaoui-Jamali MA, et al. Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors. *Cancer Research*. 2003; 63:3764–3774. [PubMed: 12839972]
88. van't Veer LJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. *Nature*. 2002; 415:530–536. [PubMed: 11823860]
89. Gruvberger S, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. *Cancer Research*. 2001; 61:5979–5984. [PubMed: 11507038]
90. van de Vijver MJ, et al. A gene-expression signature as a predictor of survival in breast cancer. *New England Journal of Medicine*. 2002; 347:1999–2009. [PubMed: 12490681]
91. Yang F, et al. Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways. *Oncogene*. 2006; 25:1413–1419. [PubMed: 16261164]
92. Saal LH, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. *Proceedings of the National Academy of Sciences of the United States of America*. 2007; 104:7564–7569. [PubMed: 17452630]
93. Finak G, et al. Stromal gene expression predicts clinical outcome in breast cancer. *Nature Medicine*. 2008; 14:518–527.
94. Ma XJ, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. *Cancer Cell*. 2004; 5:607–616. [PubMed: 15193263]

95. Zahnow CA, et al. Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer. *Journal of the National Cancer Institute*. 1997; 89:1887–1891. [PubMed: 9414177]
96. Milde-Langosch K, Loning T, Bamberger AM. Expression of the CCAAT/enhancer-binding proteins C/EBPalpha, C/EBPbeta and C/EBPdelta in breast cancer: correlations with clinicopathologic parameters and cell-cycle regulatory proteins. *Breast Cancer Research and Treatment*. 2003; 79:175–185. [PubMed: 12825852]
97. Gomis RR, et al. C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. *Cancer Cell*. 2006; 10:203–214. [PubMed: 16959612]
98. Seagroves TN, et al. C/EBPbeta, but not C/EBPalpha, is essential for ductal morphogenesis, lobuloalveolar proliferation, and functional differentiation in the mouse mammary gland. *Genes and Development*. 1998; 12:1917–1928. [PubMed: 9637692]
99. Robinson GW, et al. The C/EBPbeta transcription factor regulates epithelial cell proliferation and differentiation in the mammary gland. *Genes and Development*. 1998; 12:1907–1916. [PubMed: 9637691]
100. Seagroves TN, et al. C/EBPbeta (CCAAT/enhancer binding protein) controls cell fate determination during mammary gland development. *Molecular Endocrinology*. 2000; 14:359–368. [PubMed: 10707954]
101. Uematsu S, et al. The C/EBP beta isoform 34-kDa LAP is responsible for NF-IL-6-mediated gene induction in activated macrophages, but is not essential for intracellular bacteria killing. *Journal of Immunology*. 2007; 179:5378–5386.
102. Baldwin BR, Timchenko NA, Zahnow CA. Epidermal Growth Factor Receptor Stimulation Activates the RNA Binding Protein CUG-BP1 and Increases Expression of C/EBPbeta-LIP in Mammary Epithelial Cells. *Molecular and Cellular Biology*. 2004; 24:3682–3691. [PubMed: 15082764]
103. Bundy LM, Sealy L. CCAAT/enhancer binding protein beta (C/EBPbeta)-2 transforms normal mammary epithelial cells and induces epithelial to mesenchymal transition in culture. *Oncogene*. 2003; 22:869–883. [PubMed: 12584567]
104. Zhou J, et al. Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. *Cancer Research*. 2001; 61:2328–2334. [PubMed: 11280806]
105. Combates NJ, et al. NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter. *Journal of Biological Chemistry*. 1994; 269:29715–29719. [PubMed: 7961962]
106. Conze D, et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. *Cancer Research*. 2001; 61:8851–8858. [PubMed: 11751408]
107. Chen GK, et al. CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells. *Molecular Pharmacology*. 2004; 65:906–916. [PubMed: 15044620]
108. Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. *Endocrine-Related Cancer*. 2003; 10:43–73. [PubMed: 12653670]
109. Wessells J, Yakar S, Johnson PF. Critical prosurvival roles for C/EBP beta and insulin-like growth factor I in macrophage tumor cells. *Molecular and Cellular Biology*. 2004; 24:3238–3250. [PubMed: 15060147]
110. Yoon K, et al. Decreased survival of C/EBP beta-deficient keratinocytes is due to aberrant regulation of p53 levels and function. *Oncogene*. 2007; 26:360–367. [PubMed: 16832342]
111. Ewing SJ, et al. C/EBPbeta represses p53 to promote cell survival downstream of DNA damage independent of oncogenic Ras and p19(Arf). *Cell Death and Differentiation*. 2008; 15:1734–1744. [PubMed: 18636078]
112. Buck M, Turler H, Chojkier M. LAP (NF-IL-6), a tissue-specific transcriptional activator, is an inhibitor of hepatoma cell proliferation. *EMBO Journal*. 1994; 13:851–860. [PubMed: 7906646]

113. Zhu S, et al. C/EBPbeta modulates the early events of keratinocyte differentiation involving growth arrest and keratin 1 and keratin 10 expression. *Molecular and Cellular Biology*. 1999; 19:7181–7190. [PubMed: 10490653]
114. Johnson PF. Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors. *Journal of Cell Science*. 2005; 118:2545–2555. [PubMed: 15944395]
115. Sebastian T, et al. C/EBPbeta cooperates with RB:E2F to implement Ras(V12)-induced cellular senescence. *EMBO Journal*. 2005; 24:3301–3312. [PubMed: 16107878]
116. Acosta JC, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. *Cell*. 2008; 133:1006–1018. [PubMed: 18555777]
117. Kuilman T, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. *Cell*. 2008; 133:1019–1031. [PubMed: 18555778]
118. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. *Cell*. 2002; 110:669–672. [PubMed: 12297041]
119. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. *Nature Reviews. Cancer*. 2005; 5:341–354.
120. Zahnow CA. ErbB receptors and their ligands in the breast. *Expert Rev Molecular Medicine*. 2006; 8:1–21.
121. Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. *Breast Cancer Research and Treatment*. 1999; 53:167–176. [PubMed: 10326794]
122. Di Fiore PP, et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. *Science*. 1987; 237:178–182. [PubMed: 2885917]
123. Allred DC, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. *Human Pathology*. 1992; 23:974–979. [PubMed: 1355464]
124. Arcidiacono MV, et al. EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. *Journal of the American Society of Nephrology*. 2008; 19:310–320. [PubMed: 18216322]
125. He D, et al. Lysophosphatidic acid-induced transactivation of epidermal growth factor receptor regulates cyclo-oxygenase-2 expression and prostaglandin E(2) release via C/EBPbeta in human bronchial epithelial cells. *Biochemical Journal*. 2008; 412:153–162. [PubMed: 18294142]
126. Dickson C, et al. Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptors. *Breast Cancer Research*. 2000; 2:191–196. [PubMed: 11250709]
127. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. *Cytokine and Growth Factor Reviews*. 2005; 16:139–149. [PubMed: 15863030]
128. Klagsbrun M, Baird A. A dual receptor system is required for basic fibroblast growth factor activity. *Cell*. 1991; 67:229–231. [PubMed: 1655276]
129. Tsukamoto AS, et al. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. *Cell*. 1988; 55:619–625. [PubMed: 3180222]
130. Welm BE, et al. Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. *Journal of Cell Biology*. 2002; 157:703–714. [PubMed: 12011115]
131. Penault-Llorca F, et al. Expression of FGF and FGF receptor genes in human breast cancer. *International Journal of Cancer*. 1995; 61:170–176.
132. Zammit C, et al. Fibroblast growth factor 8 is expressed at higher levels in lactating human breast and in breast cancer. *British Journal of Cancer*. 2002; 86:1097–1103. [PubMed: 11953856]
133. Tamaru N, et al. Estrogen receptor-associated expression of keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast cancer. *Laboratory Investigation*. 2004; 84:1460–1471. [PubMed: 15311216]
134. Theodorou V, et al. Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. *Oncogene*. 2004; 23:6047–6055. [PubMed: 15208658]

135. Reis-Filho JS, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. *Clinical Cancer Research*. 2006; 12:6652–6662. [PubMed: 17121884]
136. Meijer D, et al. Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. *Endocrine-Related Cancer*. 2008; 15:101–111. [PubMed: 18310279]
137. Luqmani YA, Graham M, Coombes RC. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. *British Journal of Cancer*. 1992; 66:273–280. [PubMed: 1380281]
138. Hunter DJ, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. *Nature Genetics*. 2007; 39:870–874. [PubMed: 17529973]
139. Easton DF, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature*. 2007; 447:1087–1093. [PubMed: 17529967]
140. Meyer KB, et al. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. *PLoS Biology*. 2008; 6:e108. [PubMed: 18462018]
141. Kagan BL, et al. Complex regulation of the fibroblast growth factor-binding protein in MDA-MB-468 breast cancer cells by CCAAT/enhancer-binding protein beta. *Cancer Research*. 2003; 63:1696–1705. [PubMed: 12670924]
142. Czubayko F, et al. Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. *Journal of Biological Chemistry*. 1994; 269:28243–28248. [PubMed: 7525570]
143. Papa V, et al. Elevated insulin receptor content in human breast cancer. *Journal of Clinical Investigation*. 1990; 86:1503–1510. [PubMed: 2243127]
144. Holdaway IM, Friesen HG. Hormone binding by human mammary carcinoma. *Cancer Research*. 1977; 37:1946–1952. [PubMed: 193630]
145. Milazzo G, et al. Insulin receptor expression and function in human breast cancer cell lines. *Cancer Research*. 1992; 52:3924–3930. [PubMed: 1617668]
146. Finlayson CA, et al. Enhanced insulin signaling via Shc in human breast cancer. *Metabolism*. 2003; 52:1606–1611. [PubMed: 14669164]
147. Pekonen F, et al. Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. *Cancer Research*. 1988; 48:1343–1347. [PubMed: 2963690]
148. Foekens JA, et al. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. *Cancer Research*. 1989; 49:7002–7009. [PubMed: 2555057]
149. Bonnetterre J, et al. Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. *Cancer Research*. 1990; 50:6931–6935. [PubMed: 2170011]
150. Surmacz E. Function of the IGF-I receptor in breast cancer. *Journal of Mammary Gland Biology and Neoplasia*. 2000; 5:95–105. [PubMed: 10791772]
151. Goodwin PJ, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. *Journal of Clinical Oncology*. 2002; 20:42–51. [PubMed: 11773152]
152. Pasanisi P, et al. Metabolic syndrome as a prognostic factor for breast cancer recurrences. *International Journal of Cancer*. 2006; 119:236–238.
153. Pasanisi P, et al. Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis. *Cancer Epidemiology Biomarkers & Prevention*. 2008; 17:1719–1722.
154. Papa V, Costantino A, Belfiore A. Insulin receptor what role in breast cancer? *Trends in Endocrinology and Metabolism*. 1997; 8:306–312. [PubMed: 18406819]
155. Lu M, Seufert J, Habener JF. Pancreatic beta-cell-specific repression of insulin gene transcription by CCAAT/enhancer-binding protein beta. Inhibitory interactions with basic helix-loop-helix transcription factor E47. *Journal of Biological Chemistry*. 1997; 272:28349–28359. [PubMed: 9353292]
156. Seufert J, Weir GC, Habener JF. Differential expression of the insulin gene transcriptional repressor CCAAT/enhancer-binding protein beta and transactivator islet duodenum homeobox-1

- in rat pancreatic beta cells during the development of diabetes mellitus. *Journal of Clinical Investigation*. 1998; 101:2528–2539. [PubMed: 9616224]
157. Shen CN, et al. Glucocorticoids suppress beta-cell development and induce hepatic metaplasia in embryonic pancreas. *Biochemical Journal*. 2003; 375:41–50. [PubMed: 14509268]
158. Wang L, et al. Increased insulin receptor substrate-1 and enhanced skeletal muscle insulin sensitivity in mice lacking CCAAT/enhancer-binding protein beta. *Journal of Biological Chemistry*. 2000; 275:14173–14181. [PubMed: 10747954]
159. Foti D, et al. A nucleoprotein complex containing Sp1, C/EBP beta, and HMGI-Y controls human insulin receptor gene transcription. *Molecular and Cellular Biology*. 2003; 23:2720–2732. [PubMed: 12665574]
160. MacDougald OA, et al. Insulin regulates transcription of the CCAAT/enhancer binding protein (C/EBP) alpha, beta, and delta genes in fully-differentiated 3T3-L1 adipocytes. *Journal of Biological Chemistry*. 1995; 270:647–654. [PubMed: 7822291]
161. Le Lay S, et al. Insulin and sterol-regulatory element-binding protein-1c (SREBP-1C) regulation of gene expression in 3T3-L1 adipocytes. Identification of CCAAT/enhancer-binding protein beta as an SREBP-1C target. *Journal of Biological Chemistry*. 2002; 277:35625–35634. [PubMed: 12048207]
162. Duong DT, et al. Insulin inhibits hepatocellular glucose production by utilizing liver-enriched transcriptional inhibitory protein to disrupt the association of CREB-binding protein and RNA polymerase II with the phosphoenolpyruvate carboxykinase gene promoter. *Journal of Biological Chemistry*. 2002; 277:32234–32242. [PubMed: 12070172]
163. Bosch F, Sabater J, Valera A. Insulin inhibits liver expression of the CCAAT/enhancer-binding protein beta. *Diabetes*. 1995; 44:267–271. [PubMed: 7883112]
164. Sekine O, et al. Insulin activates CCAAT/enhancer binding proteins and proinflammatory gene expression through the phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. *Journal of Biological Chemistry*. 2002; 277:36631–36639. [PubMed: 12145301]
165. Guo S, et al. Insulin suppresses transactivation by CAAT/enhancer-binding proteins beta (C/EBPbeta). Signaling to p300/CREB-binding protein by protein kinase B disrupts interaction with the major activation domain of C/EBPbeta. *Journal of Biological Chemistry*. 2001; 276:8516–8523. [PubMed: 11116148]
166. Grimm SL, et al. Disruption of steroid and prolactin receptor patterning in the mammary gland correlates with a block in lobuloalveolar development. *Molecular Endocrinology*. 2002; 16:2675–2691. [PubMed: 12456789]
167. Noltén LA, et al. Expression of the insulin-like growth factor I gene is stimulated by the liver-enriched transcription factors C/EBP alpha and LAP. *Molecular Endocrinology*. 1994; 8:1636–1645. [PubMed: 7708053]
168. Umayahara Y, et al. Protein kinase C-dependent, CCAAT/enhancer-binding protein beta-mediated expression of insulin-like growth factor I gene. *Journal of Biological Chemistry*. 2002; 277:15261–15270. [PubMed: 11825899]
169. Umayahara Y, et al. CCAAT/enhancer-binding protein delta is a critical regulator of insulin-like growth factor-I gene transcription in osteoblasts. *Journal of Biological Chemistry*. 1999; 274:10609–10617. [PubMed: 10187857]
170. McCarthy TL, et al. Time- and dose-related interactions between glucocorticoid and cyclic adenosine 3',5'-monophosphate on CCAAT/enhancer-binding protein-dependent insulin-like growth factor I expression by osteoblasts. *Endocrinology*. 2000; 141:127–137. [PubMed: 10614631]
171. Nerlov C. The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. *Trends in Cell Biology*. 2007; 17:318–324. [PubMed: 17658261]
172. Brennan P, Donev R, Hewamana S. Targeting transcription factors for therapeutic benefit. *Molecular Biosystems*. 2008; 4:909–919. [PubMed: 18704229]
173. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. *Nature Reviews. Cancer*. 2006; 6:38–51.

174. Liu X, et al. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. *Nature*. 2008; 451:846–850. [PubMed: 18273021]
175. Zheng Y, et al. Selective HAT inhibitors as mechanistic tools for protein acetylation. *Methods in Enzymology*. 2004; 376:188–199. [PubMed: 14975306]
176. Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. *Annals of Medicine*. 2006; 38:200–211. [PubMed: 16720434]
177. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. *Oncogene*. 2008; 27:5497–5510. [PubMed: 18794884]
178. Gilmore TD, Herscovitch M. Inhibitors of NF-kappaB signaling: 785 and counting. *Oncogene*. 2006; 25:6887–6899. [PubMed: 17072334]
179. Dey A, Verma CS, Lane DP. Updates on p53: modulation of p53 degradation as a therapeutic approach. *British Journal of Cancer*. 2008; 98:4–8. [PubMed: 18182973]
180. Mees C, Nemunaitis J, Senzer N. Transcription factors: their potential as targets for an individualized therapeutic approach to cancer. *Cancer Gene Therapy*. 2009; 16:103–112. [PubMed: 18846113]
181. Rizzo P, et al. Rational targeting of Notch signaling in cancer. *Oncogene*. 2008; 27:5124–5131. [PubMed: 18758481]
182. Rishi V, et al. A high-throughput fluorescence-anisotropy screen that identifies small molecule inhibitors of the DNA binding of B-ZIP transcription factors. *Analytical Biochemistry*. 2005; 340:259–271. [PubMed: 15840499]
183. Turkson J, et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. *Journal of Biological Chemistry*. 2001; 276:45443–45455. [PubMed: 11579100]
184. Berg T, et al. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. *Proceedings of the National Academy of Sciences of the United States of America*. 2002; 99:3830–3835. [PubMed: 11891322]
185. Vassilev LT, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. *Science*. 2004; 303:844–848. [PubMed: 14704432]
186. Efeyan A, et al. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. *Cancer Research*. 2007; 67:7350–7357. [PubMed: 17671205]
187. Olenyuk BZ, et al. Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. *Proceedings of the National Academy of Sciences of the United States of America*. 2004; 101:16768–16773. [PubMed: 15556999]
188. Kozak M. An analysis of vertebrate mRNA sequences: intimations of translational control. *Journal of Cell Biology*. 1991; 115:887–903. [PubMed: 1955461]
189. Raught B, et al. Expression of a translationally regulated, dominant-negative CCAAT/enhancer-binding protein beta isoform and up-regulation of the eukaryotic translation initiation factor 2alpha are correlated with neoplastic transformation of mammary epithelial cells. *Cancer Research*. 1996; 56:4382–4386. [PubMed: 8813130]
190. Lincoln AJ, et al. Inhibition of CCAAT/enhancer-binding protein alpha and beta translation by upstream open reading frames. *Journal of Biological Chemistry*. 1998; 273:9552–9560. [PubMed: 9545285]
191. Li Y, et al. Differential control of the CCAAT/enhancer-binding protein beta (C/EBPbeta) products liver-enriched transcriptional activating protein (LAP) and liver-enriched transcriptional inhibitory protein (LIP) and the regulation of gene expression during the response to endoplasmic reticulum stress. *Journal of Biological Chemistry*. 2008; 283:22443–22456. [PubMed: 18550528]
192. Sterneck E, Tessarollo L, Johnson PF. An essential role for C/EBPbeta in female reproduction. *Genes and Development*. 1997; 11:2153–2162. [PubMed: 9303532]
193. Millward CA, et al. Mice with a deletion in the gene for CCAAT/enhancer-binding protein beta are protected against diet-induced obesity. *Diabetes*. 2007; 56:161–167. [PubMed: 17192478]
194. Carmona MC, et al. Defective thermoregulation, impaired lipid metabolism, but preserved adrenergic induction of gene expression in brown fat of mice lacking C/EBPbeta. *Biochemistry Journal*. 2005; 389:47–56.

195. Croniger CM, et al. Mice with a deletion in the gene for CCAAT/enhancer-binding protein beta have an attenuated response to cAMP and impaired carbohydrate metabolism. *Journal of Biological Chemistry*. 2001; 276:629–638. [PubMed: 11024029]
196. Liu S, et al. Hypoglycemia and impaired hepatic glucose production in mice with a deletion of the C/EBPbeta gene. *Journal of Clinical Investigation*. 1999; 103:207–213. [PubMed: 9916132]
197. Greenbaum LE, et al. CCAAT enhancer-binding protein beta is required for normal hepatocyte proliferation in mice after partial hepatectomy. *Journal of Clinical Investigation*. 1998; 102:996–1007. [PubMed: 9727068]
198. Tominaga H, et al. CCAAT/Enhancer-binding Protein fbetag Promotes Osteoblast Differentiation by Enhancing Runx2 Activity with ATF4. *Molecular Biology of the Cell*. 2008; 19:5373–5386. [PubMed: 18843047]
199. Tanaka T, et al. Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. *Cell*. 1995; 80:353–361. [PubMed: 7530603]
200. Screpanti I, et al. Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. *EMBO Journal*. 1995; 14:1932–1941. [PubMed: 7744000]
201. Tanaka T, et al. Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene. *EMBO Journal*. 1997; 16:7432–7443. [PubMed: 9405372]

Figure 1. Structure of CCAAT/enhancer-binding protein β

The position and size of the activation domains (AD) (orange), the negative regulatory domains (RD) (pink) and the conserved regions (CR) are approximated. The basic DNA-binding region and the leucine zipper are indicated in green and yellow, respectively. The amino acid numbers on the left refer to the position of the relevant initiation codon within the open reading frame of the mouse sequence. The full-length LAP1, and smaller LAP2 and LIP isoforms are shown.

Figure 2. Structure of mRNA encoding CCAAT/enhancer-binding protein β

C/EBP β is translated into several distinct protein isoforms (LAP1, LAP2 and LIP) whose expression is regulated by the alternative use of several in-frame translation start sites (Ref. 20). The 5' end of C/EBP β mRNA contains a 5'UTR of 298 bases with a GC content of approximately 73%, which has the potential to form complex, stable secondary structures that can interfere with scanning ribosomes (Refs 188,189). An upstream AUG (uAUG) and a small open reading frame (uORF) are also located in a hairpin loop of 5' C/EBP β mRNA between the translation initiation sites for LAP1 and LAP2. This region is crucial for the translational control of the C/EBP β LAP2 and LIP isoforms (Refs 190,22,23,102). LAP1 is translated by initiation of the ribosomes at the LAP1 AUG codon. LAP2 is translated by leaky ribosome scanning through the uORF AUG followed by initiation at the LAP2 AUG site. Initiation at the uAUG and translation of the uORF may prevent ribosome reinitiation at the LAP 2 AUG because of the close proximity of the uORF AUG to the LAP2 AUG. However, in some instances, immediate reinitiation after translation of the uORF may occur and this has also been proposed as a potential mechanism (Ref. 22). LIP is then translated by leaky ribosome scanning over the LAP1 AUG, followed by initiation of the uORF AUG, and ribosomal reinitiation at the LIP AUG (Ref. 23). Although LIP expression is often regulated by the 5'UTR/sORF (Ref. 22), there have also been reports that LIP expression can be regulated in a manner that is independent of the 5'UTR/sORF and that LIP protein stability may be regulated by an undefined post-translational mechanism (Ref. 191).

Figure 3. Post-translational processing of CCAAT/enhancer-binding protein β

The structural domains of C/EBPβ are identical to those shown in Fig. 1. (a) Phosphorylated serine (Ser) or threonine (Thr) are indicated with a vertical line and a number that denotes the approximate position of the phosphorylated amino acid in either the mouse (M), rat (R) or human (H) C/EBPβ protein sequence. Acetylated lysine residues are depicted as circles labelled Ac below a lysine (Lys), indicating its position in the mouse (M) sequence. The sumoylation site is represented with a red triangle, and the position of Lys residues in mouse (M) or human (H) is shown. The methylation of Lys39 is shown as a large green circle labelled M in either the chicken (C), mouse (M) or rat (R) sequence. (b) The location of the cysteine residues and the resulting disulfide bridges are shown for the mouse C/EBPβ protein sequence.

Figure 4. Generalised interactions between CCAAT/enhancer-binding protein β and receptor tyrosine kinases in several tissues

(a) EGFR (ErbB1) signalling leads to an increase in LIP expression and an increase in the ratio of LIP:LAP. (b) EGFR signalling regulates the binding of LIP and LAP to the *FGFBP1* promoter and the ratio of LIP:LAP regulates *FGFBP1* expression levels. *FGFBP1* in turn can increase the activity of FGF1 and FGF2. LAP also binds to the *FGFR2* promoter in a complex with Oct1–Runx2 to increase expression of *FGFR2*. (c) LAP expression reduces or increases insulin expression in pancreatic β cells and non-pancreatic β cells, respectively. In liver, LAP has been shown to regulate transcription of the insulin receptor as part of a larger complex containing the transcription factor HMGI-Y. In adipocytes and muscle, insulin signalling leads to increases in the expression of the LAP and LIP isoforms; however, in diabetic mouse liver, LAP expression is downregulated by elevation in insulin. (d) C/EBP β -LAP upregulates IGF-I expression in liver, macrophages and bone.

Overexpression of LIP alone has no effect on IGF-I gene promoter activity but can abolish the transactivation induced by LAP. The IGF axis is dysregulated in the mammary gland of the C/EBP β -null mouse, and IRS levels decrease in the absence of C/EBP β . Abbreviations: EGF, epidermal growth factor; FGF, fibroblast growth factor; *FGFBP1*, fibroblast growth factor binding protein-1; HMGI-Y, high-mobility group protein HMG-I/HMG-Y; IGF-I, insulin-like growth factor I; IRS, insulin-receptor substrate.

Table 1

Genes encoding CCAAT/enhancer-binding proteins in rodents and humans

Gene Family	Synonyms	Location in rodent (Chr. no.)	Location in human (Chr. no.)	Protein isoforms
C/EBP α	CEBPA, C/EBP, CBF-A	7	19q13	<p>Rodent p42, p30</p> <p>Human</p>
C/EBP β	CEBPB, NF-IL6, IL-6DBP, CRP2, LAP/LIP, TCF-5, AGP/EBP, NF-M, GPE-BP, ApC/EBP	2	20q13	<p>Rodent LAP1 (LAP*) 38 kDa LAP2 (LAP) 34 kDa LIP 20 kDa</p> <p>Human C/EBP1 44 kDa C/EBP2 42 kDa C/EBP3 20 kDa</p>
C/EBP δ	CEBPD, CRP3, CELF, NF-IL6b, R α C/EBP2	18	8p11	<p>Rodent p29</p> <p>Human</p>
C/EBP ϵ	CEBPE, CRP1	14	14q11	<p>Rodent p32, p30, p27, p14</p> <p>Human</p>
C/EBP γ	CEBPD, GCSF, Ig/EBP, GPE1-BP	7	19	<p>Rodent p16</p> <p>Human</p>
C/EBP ζ	CEBPG, CHOP10, DDIT3, GADD153, GAI5	10	12q13	<p>Rodent p19</p> <p>Human</p>

Abbreviations: AGP/EBP, α -1 acid glycoprotein/enhancer-binding protein; CBF, core binding factor; Chr. no., chromosome number; CELF, C/EBP-like factor; C/EBP, CCAAT/enhancer-binding protein; CHOP, C/EBP homologous protein; CRP, C-reactive protein; DDIT, DNA-damage-inducible transcript; GA, locus GAI5; GADD, growth arrest and DNA-damage-inducible gene; GPE-BP, G-CSF promoter-element-binding protein; IL, interleukin; NF, nuclear factor; TCF5, transcription factor 5.

Table 2

CCAAT/enhancer-binding protein β phosphorylation sites

Species	Residue	Upstream effector	Kinase	Downstream effect	Cell type	Reference
Human Mouse Rat	Thr235 Thr188 Thr189	Oncogenic Ras overexpression	MAPK	Increases transcriptional activation of C/EBP β	NIH 3T3 Fibroblasts, P19 embryonic carcinoma cells	Ref. 38
Mouse	Thr188 Dephosphorylated Thr188	Activated Ras Growth hormone	MAPK Cdk2/cyclinA PI3K/Akt-mediated inhibition of GSK3 β	Increases transcriptional activation of C/EBP β Increases binding of LAP-LAP and LAP-LIP, but not LIP-LIP to Fos promoter	NIH 3T3 fibroblasts, BALB/MK2 keratinocytes, 3T3-L1 Pre-adipocytes, 3T3-F442A fibroblasts	Refs 39,41, 42,43
Chicken	MAPK-sensitive residues Thr188? Ser64?	Ras/MAPK	MAPK-induced structural associations of NF-M (C/EBP β) with mediator complexes via CRSP130/Sur2	Increases transcriptional activation of NF-M (C/EBP β)	HeLa cells, Quail fibroblast Q16 cells	Ref. 40
Mouse	Thr179 Ser184	Adipogenesis	GSK 3 β	Increases DNA binding of C/EBP β	3T3-L1 pre-adipocytes	Ref. 43
Mouse	Ser276	A23187	Ca ²⁺ /calmodulin-dependent protein kinase (CaM kinase II)	Increases transcriptional activation of C/EBP β	G/C rat pituitary tumour cells	Ref. 44
Rat	Ser105	TGF- α	Ribosomal S6 kinase (RSK) P90RSK	Increases transcriptional activation of C/EBP β and proliferation of differentiated hepatocytes or HSCs	Human HepG2 hepatoma cells, Primary rat/mouse hepatocytes	Ref. 46
Rat	Ser105	TPA	Protein kinase C via indirect effect	Increases Transcriptional Activation of C/EBP β	Human HepG2 hepatoma cells	Ref. 48
Rat		Forskolin	cAMP signalling	Increases nuclear translocation of C/EBP β and activation of Fos gene	PC12 rat pheochromocytoma cells	Ref. 47
Human	Ser 261 Ser 288	Pyrrolidinedithiocarbamate (Antioxidant)	Protein kinase A	Increases nuclear translocation of C/EBP β	DKO colorectal cancer cells	Ref. 51
Rat	Ser105 Ser240 (Ser173-Ser223) Ser 240		Protein kinase A Protein kinase A Protein kinase C	No effect on DNA binding Inhibition of DNA binding Inhibition of DNA binding	In vitro assays: phosphorylation of Ser240 not detected in intact cells	Ref. 49
Human	Ser261 (277)? Ser288 (299)?		Protein kinase C	Inhibition of DNA binding	In vitro assays	Ref. 50

Abbreviations: CCl₄, carbon tetrachloride; DKO, double knockout; GSK 3 β , glycogen synthase kinase 3 beta; HSCs, hepatic stellate cells; MAPK, mitogen-activated protein kinase; TGF- α , transforming growth factor α ; TPA, 12-O-tetradecanoyl-phorbol-13-acetate.

Genetically engineered mouse models provide insight into the actions of the LAP1, LAP2 and LIP isoforms

Table 3

Mouse model	Tissue	Defect observed	Reference
C/EBP $\beta^{-/-}$ mice ^a	Mammary gland	Delayed ductal outgrowth, ductal ectasia, decreased branching, reduced secretory activity and decreased levels of the milk proteins β -casein and WAP	Refs 98,99
C/EBP $\beta^{-/-}$ mice	Ovary	Impaired ovarian granulosa cell differentiation resulting in sterility	Ref. 192
C/EBP $\beta^{-/-}$ mice	White adipocytes	Impaired lipid metabolism: reduced levels of acetyl CoA carboxylase, fatty acid synthase, blood triglycerides, free fatty acids, cholesterol, and hepatic triglyceride accumulation	Ref. 193
	Brown adipocytes	Impaired brown fat thermogenesis	Ref. 194
C/EBP $\beta^{-/-}$ mice	Liver	Impaired carbohydrate metabolism	Ref. 195
C/EBP $\beta^{-/-}$ mice	Liver and adipocytes	Impaired lipid and glucose homeostasis: exhibit fasting hypoglycaemia, decreased blood lipids, impaired hepatic glucose output and adipose tissue lipolysis in response to hormone stimulation	Ref. 196
C/EBP $\beta^{-/-}$ mice	Liver	Impaired liver proliferation and regeneration	Ref. 197
C/EBP $\beta^{-/-}$ mice	Epidermis	Impaired stratified, squamous differentiation of keratinocytes	Ref. 113
C/EBP $\beta^{-/-}$ mice	Bone	Delayed bone formation with concurrent suppression of chondrocyte maturation and osteoblast differentiation	Ref. 19
C/EBP $\beta^{-/-}$ mice	Peritoneal macrophages	Impaired antibacterial, inflammatory and antitumour defences	Ref. 199
C/EBP $\beta^{-/-}$ mice	Haematopoietic and lymphoid compartments	Impaired humoral, innate and cellular immunity, accompanied by marked splenomegaly, enhanced haematopoiesis, and peripheral lymphadenopathy	Ref. 200
C/EBP $\beta^{-/-}$ mice and C/EBP $\delta^{-/-}$ mice	Adipocyte development	Impairment of adipocyte differentiation	Ref. 201
C/EBP $\beta^{M20A/M20A}$ mice (lacking LAP2 (34 kDa))	Peritoneal macrophages	Impaired NF-IL-6-mediated gene induction	Ref. 101
WAP-LIP transgenic mice	Mammary gland	Development of focal and diffuse alveolar hyperplasia, and invasive and non-invasive	Ref. 69

Mouse model	Tissue	Defect observed	Reference
Coll1 ^a -LIP transgenic mice	Bone	carcinomas Impaired osteoblast differentiation, development of osteopaenia and reduced bone formation	Ref. 70
Coll1 ^a -LIP transgenic mice	Incisors	Malocclusion, overgrowth and fragility of the incisors resulting from impairment of odontoblast differentiation and dentin matrix production	Ref. 71

Abbreviations: C/EBP, CCAAT/enhancer-binding protein; WAP, whey acidic protein.

^aC/EBPβ^{-/-} mice lack LAP1, LAP2 and LIP.

Table 4

Oncomine Research Cancer-profiling Database

Study	Tissue	Sample number	P-value	Result	Reference
Oestrogen receptor status of breast carcinoma and C/EBP β mRNA expression van de Vijver	Breast carcinoma	ER - (69) ER + (226)	0.00000075	Increases in C/EBP β mRNA associated with ER-negative breast tumours	Ref. 90
	Breast carcinoma	ER - (30) ER + (28)	0.0000017	Increases in C/EBP β mRNA associated with ER-negative breast tumours	Ref. 89
	Breast Carcinoma	ER - (60) ER + (45)	0.0000022	Increases in C/EBP β mRNA associated with ER-negative breast tumours	Ref. 92
	Breast carcinoma stroma	ER - (10) ER + (43)	0.0007	Increases in C/EBP β mRNA associated with ER-negative breast tumours	Ref. 93
Breast cancer prognosis or survival and C/EBP β mRNA expression van de Vijver	Breast carcinoma	No metastasis (194) Metastasis (101)	0.00086	Increases in C/EBP β mRNA associated with metastasis	Ref. 90
	Breast carcinoma	Alive (232) Deceased (48)	0.005	Increases in C/EBP β mRNA associated with death of patient	Ref. 90
	Breast carcinoma	Disease free (196) Relapse (79)	0.007	Increases in C/EBP β mRNA associated with recurrence	Ref. 90
	Breast carcinoma stroma	No recurrence (8) Recurrence (11)	0.013	Increases in C/EBP β mRNA associated with recurrence	Ref. 93
van de Vijver (5-year survival)	Breast carcinoma	No recurrence (26) Recurrence (14)	0.04	Increases in C/EBP β mRNA associated with recurrence	Ref. 94
van de Vijver (5-year disease free)	Breast carcinoma				
Finak (5-year recurrence)	Breast carcinoma				
Ma (5-year disease free)	Breast carcinoma				

Study	Tissue	Sample number	P-value	Result	Reference
Grade of breast carcinoma and C/EBP β mRNA expression Finak	Breast carcinoma stroma	Tumour Grade 1 (3)	0.000091	Increases in C/EBP β mRNA associated with increased tumour grade	Ref. 93
		Tumour Grade 2 (23)			
		Tumour Grade 3 (27)			
vantVeer	Breast carcinoma	Tumour Grade 1 (12)	0.00018	Increases in C/EBP β mRNA associated with increased tumour grade	Ref. 88
		Tumour Grade 2 (27)			
		Tumour Grade 3 (78)			
Ma	Breast carcinoma	Tumour Grade 1 (3)	0.045	Increases in C/EBP β mRNA associated with increased tumour grade	Ref. 94
		Tumour Grade 2 (39)			
		Tumour Grade 3 (18)			

Abbreviations: C/EBP, CCAAT/enhancer-binding protein; ER, oestrogen (estrogen) receptor.